Analysis of glycated serum proteins in type 2 diabetes patients with nephropathy

Biotechnology and Bioprocess Engineering

Volumn 19, Issue 1, 2014, Pages 83-92

  Kim, Mi Ryung ^a,b   Yu, Shin Ae ^b   Kim, Mi Yeon ^b   Choi, Kyung Mook ^c   Kim, Chan Wha ^b  

^a Silla University   (South Korea)

^b Korea University   (South Korea)

^c Korea University College of Medicine   (South Korea)

Author keywords

biomarker; fructosamine; glycation; glycoproteome; type 2 diabetic nephropathy

Indexed keywords

BIOMARKERS; BODY FLUIDS; CHAINS; DISEASES; ELECTROPHORESIS; GLYCOSYLATION;

FRUCTOSAMINE; GLYCATION; GLYCEMIC CONTROL; GLYCOPROTEOME; MICROALBUMINURIA; PROTEOMIC APPROACHES; TWO-DIMENSIONAL ELECTROPHORESIS (2-DE); TYPE 2 DIABETIC NEPHROPATHY;

PROTEINS;

CLUSTERIN; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C4B3; FRUCTOSAMINE; GLYCOSYLATED PROTEIN; HEMOGLOBIN A1C; HEMOPEXIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN MU CHAIN; PLASMA PROTEIN; PREKALLIKREIN; PROTEIN PRECURSOR; SILVER NITRATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; FRUCTOSAMINE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; MICROALBUMINURIA; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; QUADRUPOLE MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS;

EID: 84896959576     PISSN: 12268372     EISSN: 19763816     Source Type: Journal    
DOI: 10.1007/s12257-013-0464-4     Document Type: Article

References (43)

1. Korc, M. (2003) Diabetes mellitus in the era of proteomics. Mol. Cell Proteomics 2: 399-404.
2. Abou-Seif, M. A. and A. A. Youssef (2004) Evaluation of some biochemical changes in diabetic patients. Clin. Chim. Acta 346: 161-170. (Pubitemid 38901047)
3. Brownlee, M. (1995) The pathological implications of protein glycation. Clin. Invest. Med. 18: 275-281.
4. Brownlee, M. (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
5. Ritz, E., I. Rychlik, F. Locatelli, and S. Halimi (1999) End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am. J. Kidney Dis. 34: 795-808. (Pubitemid 29521694)
6. Rao, P. V., X. Lu, M. Standley, P. Pattee, G. Neelima, G. Girisesh, K. V. Dakshinamurthy, C. T. Roberts, and S. R. Nagalla (2007) Proteomic identification of urinary biomarkers of diabetic nephropathy. Diab. Care 30: 629-637. (Pubitemid 46354345)
7. Steinke, J. M., A. R. Sinaiko, M. S. Kramer, S. Suissa, B. M. Chavers, M. Mauer and International Diabetic Nephropathy Study Group (2005) The early natural history of nephropathy in Type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 54: 2164-2171. (Pubitemid 40911280)
8. Matheson, A., M. D. Willcox, J. Flanagan, and B. J. Walsh (2010) Urinary biomarkers involved in type 2 diabetes: A review. Diab. Metab. Res. Rev. 26: 150-171.
9. Ahmed, N. (2005) Advanced glycation endproducts - role in pathology of diabetic complications. Diab. Res. Clin. Pract. 67: 3-21.
10. Raj, D. S., D. Choudhury, T. C. Welbourne, and M. Levi (2000) Advanced glycation end products: A Nephrologist's perspective. Am. J. Kidney Dis. 35: 365-380.
11. Ulrich, P. and A. Cerami (2001) Protein glycation, diabetes, and aging. Recent Prog. Horm. Res. 56: 1-21.
12. Jaleel, A., P. Halvatsiotis, B. Williamson, P. Juhasz, S. Martin, and K. S. Nair (2005) Identification of Amadori-modified plasma proteins in type 2 diabetes and the effect of short-term intensive insulin treatment. Diab. Care 28: 645-652. (Pubitemid 40315326)
13. Schalkwijk, C. G., N. Chaturvedi, H. Twaafhoven, V. W. van Hinsbergh, and C. D. Stehouwer (2002) Amadori-albumin correlates with microvascular complications and precedes nephropathy in type 1 diabetic patients. Eur. J. Clin. Invest. 32: 500-506. (Pubitemid 36223420)
14. Chase, H. P., W. E. Jackson, S. L. Hoops, R. S. Cockerham, P. G. Archer, and D. O'Brien (1989) Glucose control and the renal and retinal complications of insulin-dependent diabetes. JAMA 261: 1155-1160. (Pubitemid 19062449)
15. Sullivan, K. A. and E. L. Feldman (2005) New developments in diabetic neuropathy. Curr. Opin. Neurol. 18: 586-590. (Pubitemid 41476148)
16. Allgrove, J. and B. L. Cockrill (1988) Fructosamine or glycated haemoglobin as a measure of diabetic control? Arch. Dis. Child. 63: 418-422.
17. Zhang, Q., N. Tang, A. A. Schepmoes, L. S. Phillips, R. D. Smith, and T. O. Metz (2008) Proteomic profiling of nonenzymatically glycated proteins in human plasma and erythrocyte membranes. J. Proteome Res. 7: 2025-2032.
18. Ryu, J. K., H. S. Kim, and D. H. Nam (2012) Current status and perspectives of biopharmaceutical drugs. Biotechnol. Bioproc. Eng. 17: 900-911.
19. Cheng, J. S., X. M. Lv, and Y. J. Yuan (2012) Investigation of proteomic responses of streptomyces lydicus to pitching ratios for improving streptolydigin production. Biotechnol. Bioproc. Eng. 17: 997-1007.
20. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
21. Baker, J. R., D. V. Zyzak, S. R. Thorpe, and J. W. Baynes (1994) Chemistry of the fructosamine assay: D-glucosone is the product of oxidation of Amadori compounds. Clin. Chem. 40: 1950-1955. (Pubitemid 24332701)
22. Johnson, R. N., P. A. Metcalf, and J. R. Baker (1983) Fructosamine: A new approach to the estimation of serum glycosylprotein; An index of diabetic control. Clin. Chim. Acta 127: 87-95. (Pubitemid 13168108)
23. Kim, H. J., E. H. Cho, J. H. Yoo, P. K. Kim, J. S. Shin, M. R. Kim, and C. W. Kim (2007) Proteome analysis of serum from type 2 diabetics with nephropathy. J. Proteome. Res. 6: 735-743.
24. Cho, E. H., M. R. Kim, H. J. Kim, D. Y. Lee, P. K. Kim, K. M. Choi, O. H. Ryu, and C. W. Kim (2007) The discovery of biomarkers for type 2 diabetic nephropathy by serum proteome analysis. Proteomics-Clin. Appl. 1: 352-361.
25. Shurraw, S., B. Hemmelgarn, M. Lin, S. R. Majumdar, S. Klarenbach, B. Manns, A. Bello, M. James, T. C. Turin, and M. Tonelli (2011) Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease. Arch. Intern. Med. 171: 1920-1927.
26. Lapolla, A., L. Molin, and P. Traldi (2013) Protein glycation in diabetes as determined by mass spectrometry. Int. J. Endocrinol. 2013: 11-21.
27. Tombran-Tink, J. and L. V. Johnson (1989) Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest. Ophthalmol. Vis. Sci. 30: 1700-1707. (Pubitemid 19214990)
28. Jenkins, A., S. X. Zhang, A. Gosmanova, C. Aston, A. Dashti, M. Z. Baker, T. Lyons, and J. X. Ma (2008) Increased serum pigment epithelium derived factor levels in tye 2 diabetes patients. Diab. Res. Clin. Pr. 82: 5-7.
29. Chen, H., Z. Zheng, R. Li, J. Lu, Y. Bao, X. Ying, R. Zeng, and W. Jia (2010) Urinary pigment epithelium-derived factor as a marker of diabetic nephropathy. Am. J. Nephrol. 32: 47-56.
30. Müller-Eberhard, U. (1988) Hemopexin. Methods Enzymol. 163:536-565.
31. Zhang, Q., M. E. Monroe, A. A. Schepmoes, T. R. W. Clauss, M. A. Gritsenko, D. Meng, V. A. Petyuk, R. D. Smith, and T. O. Metz (2011) Comprehensive identification of glycated peptides and their glycation motifs in plasma and erythrocytes of control and diabetic subjects. J. Proteome Res. 10: 3076-3088.
32. Trougakos, I. P., M. Poulakou, M. Stathatos, A. Chalikia, A. Melidonis, and E. S. Gonos (2002) Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp. Gerontol. 37: 1175-1187. (Pubitemid 35418275)
33. Jaffa, A. A., R. Durazo-Arvizu, D. Zheng, D. T. Lackland, S. Srikanth, W. T. Garvey, and A. H. Schmaier (2003) Plasma prekallikrein: Plasma prekallikrein: A risk marker for hypertension and nephropathy in type 1 diabetes. Diabetes 52: 1215-1221. (Pubitemid 36523359)
34. Herwald, H., T. Renné, J. C. M. Meijers, D. W. Chung, J. D. Page, R. W. Colman, and W. Müller-Esterl (1996) Mapping of the discontinuous kininogen binding site of prekallikrein. A distal binding segment is located in the heavy chain domain A4. J. Bio. Chem. 271: 13061-13067.
35. Kedzierska, K., K. Ciechanowski, E. Go embiewska, K. Safranow, A. Ciechanowicz, L. Doma ski, M. My lak, and J. Ró a ski (2005) Plasma prekallikrein as a risk factor for diabetic retinopathy. Arch. Med. Res. 36: 539-543. (Pubitemid 41140062)
36. Mijovic, C., J. Fletcher, A. R. Bradwell, T. Harvey, and A. H. Barnett (1985) Relation of gene expression (allotypes) of the fourth component of complement to insulin dependent diabetes and its microangiopathic complications. BMJ 291: 9-10. (Pubitemid 15068792)
37. Yamagishi, S., T. Matsui, H. Adachi, and M. Takeuchi (2010) Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population. Pharmacol. Res. 61: 103-107.
38. Yamagishi, S., T. Matsui, K. Nakamura, M. Takeuchi, and T. Imaizumi (2006) Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvasc. Res. 72: 86-90. (Pubitemid 44118388)
39. Muranjan, M., V. Nussenzweig, and S. Tomlinson (1998) Characterization of the human serum Trypanosome toxin, Haptoglobin-related Protein. J. Bio. Chem. 273: 3884-3887. (Pubitemid 28103245)
40. Epelbaum, R., C. Shalitin, R. Segal, C. Valansi, I. Arselan, D. Faraggi, M. M. Leviov, M. B. Shahar, and N. Haim (1998) Haptoglobin-related protein as a serum marker in malignant lymphoma. Pathol. Oncol. Res. 4: 271-276. (Pubitemid 29081097)
41. Asleh, R. and A. P. Levy (2005) In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vas Heal. Risk Manag. 1: 19-28.
42. Samir, M. A., A. S. Suleiman, M. A. S. Qasem, and H. Hisham (2008) Association of haptoglobin phenotypes with markers of diabetic nephropathy in Type 2 diabetes mellitus. J. Diab. Compl. 22: 384-388.
43. Phadke, M., F. R. Billimoria, and V. Ninjoor (1998) Non enzymatic glycosylation of alpha-1-proteinase inhibitor of human plasma. J. Postgrad. Med. 44: 29-34. (Pubitemid 128527755)